Introduction
Orexin neuropeptides (orexin-A and -B), also known as hypocretin-1 and -2 (de Lecea et al., 1998; , act via two G-protein-coupled receptors to influence multiple homeostatic systems, including those controlling reward and arousal (Carter et al., 2009) . Indeed, orexins are critical for normal waking and sleep because the loss of orexin signaling results in the sleep disorder narcolepsy with cataplexy in animals and humans Lin et al., 1999; Peyron et al., 2000; Thannickal et al., 2000) .
The dorsal raphe (DR) and other monoaminergic nuclei receive strong orexinergic innervation , express orexin receptors (OxRs) (Trivedi et al., 1998; Marcus et al., 2001) and are targets through which orexin promotes arousal, suppresses sleep (Piper et al., 2000) , and prevents cataplexy in narcolepsy (Hasegawa et al., 2014) . Serotonergic (5-HT) DR neurons have extensive ascending projections, where 5-HT acts to regulate mood, reward, feeding, arousal and motor behavior, and is implicated in the etiology and treatment of psychiatric disorders, including depression (for review, see Jacobs and Fornal, 1999; Lowry et al., 2005) . Thus, factors influencing output from these neurons will widely impact CNS function.
5-HT DR neurons fire slowly at tonic rates that vary with behavioral state, having their highest rates in active waking and near-zero rates during REM sleep (for review, see Monti, 2011) . Some 5-HT neurons also show a "cluster" or "burst" firing, which augments 5-HT release (Hajó s et al., 2007) and occurs mostly during waking (Sakai, 2011) , when orexin neurons are most active (Lee et al., 2005b; Mileykovskiy et al., 2005) . 5-HT neurons also phasically encode sensory/motor events and reward magnitude (Ranade and Mainen, 2009; Liu et al., 2014) , and the majority of these neurons burst during sucrose reward acquisition (Li et al., 2016) . While orexin neurons fire during reward acquisition , how orexins might influence these firing patterns of 5-HT DR neurons is unknown. Orexins produce slow depolarizations throughout the CNS (for review, see Leonard and Kukkonen, 2014) , which result mainly from a noisy cation current in DR 5-HT neurons (Brown et al., 2002; Liu et al., 2002; Kohlmeier et al., 2008) . Orexins can also regulate transmitter release, which is associated with increased GABAergic input and decreased excitatory input (Haj-Dahmane and Shen, 2005) to 5-HT neurons, suggesting a multifaceted role in regulating DR output. The firing of DR 5-HT neurons is strongly regulated by a postspike afterhyperpolarization (AHP) (Aghajanian and Vandermaelen, 1982) , mediated by apamin-sensitive, SK-type, Ca 2ϩ -dependent K ϩ channels (Freedman and Aghajanian, 1987; Pan et al., 1994; Scuvée-Moreau et al., 2004; Crawford et al., 2010; Alix et al., 2014 ) that promotes slow firing (Rouchet et al., 2008) .
Here we show that orexin-A enhances this AHP and that this orexin-enhanced AHP (oeAHP) results from two distinct mechanisms, including both an increased SK current and the induction of a novel slow-AHP-like current. Moreover, our functional studies establish that the oeAHP promotes slower and more regular firing than expected for depolarizing orexin currents, and that it preserves responsiveness to phasic inputs while attenuating responsiveness to tonic inputs. Collectively, our findings reveal a new modulatory action of orexin that plays a previously unexpected role in shaping excitability of 5-HT DR neurons to better encode phasic sensory, motor, and reward signals expected during aroused states.
Materials and Methods
All procedures complied with National Institutes of Health guidelines and were approved by New York Medical College Institutional Animal Care and Use Committee.
Mice and genotyping. Brain slices were prepared from young male and female C57BL/6N mice (Charles River) and OX 1 receptor null, OX 2 receptor null, or double OxR knock-out (DKO) mice (P14-P26). Receptor knock-out mice were offspring from homozygous null breeders having a mixed C57BL6 and 129/Sv genetic background (kindly provided by Drs. M. Yanagisawa and R. Chemelli). Use of these mice has been described previously (Willie et al., 2003; Mieda et al., 2011; Kohlmeier et al., 2013) . To confirm the genotype of each mouse, tail biopsies were obtained during slice preparation and analyzed by PCR to determine whether each receptor was wild-type or knockout. The three primers for OX 1 consisted of a common primer (5Ј CTCTTTCTCCACAGAGCCCAGGACTC 3Ј), a knock-out primer (5Ј TGAGCGAGTAACAACCCGTCGGATTC 3Ј), and a wild-type primer (5Ј gCAAGAATGGGTATGAAGGGAAGGGC 3Ј). The expected product sizes were ϳ320 bp for the wild-type allele and ϳ500 bp for the knock-out allele. The three primers for OX 2 consisted of a common primer (5Ј CTG GTGCAAATCCCCTGCAAA 3Ј), a knock-out primer (5Ј GGTTTTCC CAGTCACGACGTTGTA 3Ј), and a wild-type primer (5Ј AATC CTTCTAGAGATCCCTCCTAG 3Ј). The expected product sizes were ϳ620 bp for wild-type allele and ϳ300 bp for the knock-out allele. These two sets of primers for different OxRs were processed separately, and PCR was performed using 35 cycles of 30 s at 94°C, 30 s at 62°C and 1 min at 72°C, followed by one cycle at 72°C for 10 min. The result of each PCR was then fractionated on a 2% agarose gel, and the PCR product was visualized by ethidium bromide staining.
Brain slice preparation. Mice were decapitated following induction of deep anesthesia with isofluorane. A block of brain with the target structure was rapidly removed and incubated and then cut in ice-cold ACSF, which contained the following (in mM): 124 NaCl, 5 KCl, 1.2 NaH 2 PO 4 , 2.7 CaCl 2 , 1.2 MgSO 4 , 26 NaHCO 3 , and 10 dextrose (295-305 mOsm) and was oxygenated with carbogen (95% O 2 /5% CO 2 ). Brain slices (250 m) were cut with a Leica vibratome (VT1000S) and were then incubated at 35°C for 15 min in oxygenated ACSF. They were then stored in continuously oxygenated ACSF at room temperature until use. For recordings, slices were submerged in a chamber that was perfused at 1-2 ml/min with continuously oxygenated ACSF, which was at room temperature (23 Ϯ 2°) for all experiments, except those examining the firing properties with current clamp and dynamic clamp. For those experiments, slices were superfused with ACSF maintained at 32 Ϯ 1°(see Figs. 9; 10) .
Drugs and experimental solutions. Ionotropic receptor antagonists DNQX (15 M, Sigma), AP5 (50 M, Sigma, Tocris Bioscience), and SR-95531 (gabazine, 20 M, Sigma) with strychnine (2.5 M, Sigma) were added to ACSF in all experiments to block synaptic potentials. In voltage-clamp experiments, TTX (500 nM, Alomone Labs) was added to block voltage-gated sodium channels. Orexin-A (Peptides International, 3-300 nM) was diluted into ACSF to final concentration from frozen aliquots just before use. Apamin (100 or 300 nM, Tocris Bioscience), cyclopiazonic acid (CPA; 10 M, Sigma), phenylephrine (PE; 300 nM to 30 M, Sigma), and prazosin (100 nM, Tocris Bioscience) were dissolved in ultrapure water at stock concentration and then dissolved in ACSF the day of the experiment. UCL2077 (10 M, Tocris Bioscience) was dissolved in DMSO at 5000 times final concentration. Adenylyl cyclase activator forskolin (10 M, Tocris Bioscience) was also dissolved in DMSO at 2000 times final concentration. Protein kinase C inhibitor peptide 19 -36 (PKCIP; 2 M, Calbiochem) was dissolved in pipette solution at 200 M and then further dissolved to final concentration in pipette solution on the day of the experiment. PKC inhibitor bisindolylmaleimide I (Bis I; 1 M, Calbiochem) was dissolved in water at a stock concentration. PKC activator phorbol 12,13-dibutyrate (PDBu; 1 M, Tocris Bioscience) was dissolved in DMSO at 10 4 times final concentration. Phospholipase C (PLC) inhibitor U73122 (1 M, Tocris Bioscience) and U73343 (1 M, Tocris Bioscience), the inactive analog of U73122, were dissolved in DMSO at 1000 times final concentration just before use, then diluted in pipette solution at final concentration. 5-HT (30 M, Tocris Bioscience) was dissolved in ultrapure water at stock concentration and then dissolved in ACSF at final concentration the day of the experiment. Xestospongin C (XeC; 1 M, Tocris Bioscience) and 2-aminoethoxydiphenylborane (2-APB; 50 M, Tocris Bioscience) were dissolved in DMSO at 1000 and 2000 times final concentration, then diluted in pipette solution at final concentration, respectively. Ruthenium Red (RuR, 100 M, Sigma) was dissolved in ultrapure water at 10 mM and then dissolved in pipette solution at final concentration the day of the exper-iment. Voltage-dependent potassium channel blocker 4-aminopyridine (4-AP; 5 mM, 0.5 mM, Sigma) was directly dissolved in ACSF at final concentration.
Whole-cell electrophysiological recording, imaging, IP3, and Ca 2ϩ uncaging. Whole-cell recordings (seals Ͼ 3 G⍀) with simultaneous Ca 2ϩ imaging were obtained from neurons in the DR and other structures (tuberomammilary nucleus [TMN] or laterodorsal tegmental nucleus [LDT]) as previously described (Kohlmeier et al., 2008) . Briefly, borosilicate micropipettes (2-4 M⍀; catalog #8050, AM Systems) were used and neurons were visualized for whole-cell recordings at 160 ϫ magnification using visible or near IR light, differential interference contrast optics, and a Nuvicon tube camera (Dage VE-1000) mounted on a fixed-stage microscope (Olympus, BX50WI).
Our normal pipette solution contained the following (in mM): 144 K-gluconate, 3 MgCl 2 , 10 HEPES, 0.3 NaGTP, and 4 Na 2 ATP (310 mOsm), and Bis-fura-2 (50 M; Invitrogen) was added for calciumimaging experiments. For strong and fast calcium buffering, the pipette solution contained 104 K-gluconate, 3 MgCl 2 , 10 HEPES, 0.3 NaGTP, 4 Na 2 ATP, and 10 K 4 -BAPTA. Biotinylated Alexa-594 (25 M; Invitrogen) was included in all experiments for cell identification.
To isolate and measure whole-cell Ca 2ϩ currents, the pipette solution contained the following (in mM): 144 Cs-methanesulfonate, 3 MgCl 2 , 10 HEPES, 0.3 NaGTP, and 4 Na 2 ATP, pH adjusted to 7.3 with CsOH, and the ACSF contained the following (in mM): 124 NMDG, 5 KCl, 1.25 NaH 2 PO 4 , 0.25 CaCl 2 , 3.65 MgSO 4 , 26 NaHCO 3 , and 10 dextrose (295-305 mOsm).
To isolate and measure whole-cell K ϩ currents, the normal pipette solution was used and the ACSF contained the following (in mM): 125.25 NaCl, 5 KCl, 2.7 CoCl 2 , 1.2 MgCl 2 , 26 NaHCO 3 , and 10 dextrose. Cobalt was added to the ACSF just before each experiment.
Gigaseals were obtained using an Axopatch 200B amplifier (Molecular Devices) operated in voltage-clamp mode, filtered at 2 or 5 kHz, and sampled at 20 kHz. Imaging experiments were conducted using a 40ϫ water-immersion objective (0.8 NA) with a MicroMax camera (Roper Scientific) equipped with an EEV 57 frame-transfer chip (field size ϭ 160 m/side). Bis-fura-2 was excited at 380 nm using a shuttered 75 W xenon lamp.
Whole-cell recordings were either conducted in voltage-clamp or "Iclamp fast" mode, following pipette capacitance compensation; the quality of the recording was assayed by monitoring holding current, access resistance and input resistance as determined by the voltage or current response to a brief, negative going step. These parameters were monitored throughout the recording, and data were discarded from analysis if access resistance became unstable or changed by ϳϾ20% between measurements. Recordings were also terminated if cell parameters became unstable. In most experiments, current and voltage traces were digitized and command pulses were generated with custom software (TIWB) (Inoue et al., 1998) run on a Mac OS computer controlling an ITC-18 interface (Instrutech-HEKA) that ensured precise synchronization between electrophysiological and optical signals.
Images were binned on the chip at 4 ϫ 4 and read out through a 1 MHz, 14 bit A/D converter. Images were acquired every 50 ms, a rate fast enough to monitor changes in [Ca 2ϩ ] i accompanying rapid alterations of the membrane potential. Changes in fluorescence (dF/F) were quantified from the average pixel values of regions of interest (ROIs) placed on the fluorescence images. dF was calculated as the difference between the backgroundsubtracted ROI value for each frame minus the background-subtracted baseline fluorescence. The background was taken from the value of an ROI positioned remotely from the filled cell. Baseline fluorescence was the average ROI values measured over the first few frames of each sequence before stimulation. dF was then divided by the background-subtracted baseline fluorescence to compute dF/F. Because Bis-Fura-2 fluorescence resulting from excitation at 380 nm decreases with calcium binding, dF/F responses have been inverted for clarity.
Postspike AHPs were evoked by firing single action potentials with brief (2-3 ms) current pulses adjusted to be suprathreshold, or by a 5 spike protocol consisting of a train of 5 suprathreshold current pulses (2-3 ms each at 20 Hz). To compare these AHPs, baseline membrane potential was adjusted to identical values of Ϫ65 or Ϫ70 mV by direct current injection.
AHP currents were evoked with a 5 pulse protocol consisting of a train of 5 depolarizing voltage steps to Ϫ5 mV (10 ms duration, 20 Hz) from a holding potential of Ϫ65 mV and delivered every ϳ30 s. To compute the AHP current altered by orexin, leak-corrected membrane current evoked by the 5 pulse protocol was subtracted from the leak-corrected current evoked by the 5 pulse protocol during orexin action. Because AHP currents were measured at the holding potential, leak correction was accomplished by subtracting the average holding current just before delivering each 5 pulse protocol.
Isolated Ca 2ϩ and K ϩ currents were evoked and recorded using PCLAMP 8 software (Molecular Devices, RRID: SCR_011323) running on a PC using a Digidata 1322 (Molecular Devices). Voltage and current traces were low pass filtered at 2 kHz and sampled at 20 kHz. Leakage currents and uncompensated capacitive components were subtracted using a ϪP/4 method, implemented in Clampex 8, and both the subtracted and raw current traces were acquired.
Isolated Ca 2ϩ currents were monitored before and after orexin application by 30 ms step depolarizations to Ϫ25 mV from a holding potential of Ϫ65 mV, delivered every 30 s, and confirmed by blockade with extracellular Co 2ϩ (2.7 mM). To measure isolated K ϩ currents, three sets of voltage-clamp experiments were performed before and after orexin application. From a holding potential of Ϫ65 mV, delayed rectifier current was elicited by a series of activation pulses from Ϫ95 mV to Ϫ5 mV in 10 mV increments following a 300 ms inactivation pulse to Ϫ45 mV. To elicit a transient outward current, the same protocol was repeated with a 150 ms deinactivating prepulse to Ϫ105 mV preceding the activation steps. The transient currents were then computed by subtracting the first series of currents from the second series of current. A third series of pulses to measure the voltage dependence of inactivation was delivered from a holding potential of Ϫ65 mV. An initial 150 ms inactivating pulse to Ϫ45 mV was followed by a 150 ms prepulse that varied from Ϫ105 mV to Ϫ35 mV in 10 mV increments and was followed by a 150 ms test pulse to Ϫ15 mV. The transient current was computed by subtracting the delayed rectifier current elicited by a test pulse preceded by a prepulse to Ϫ35 mV. For both Ca 2ϩ -and K ϩ -current recordings, uncompensated series resistance was between 4 and 11 M⍀ and was electronically corrected by 40%-75%.
Repetitive firing was elicited with constant current steps of 5 s duration and amplitudes from 50 to 300 pA, delivered once every 20 s. The ability to fire spikes in response to different frequency trains of stimuli was assessed with 10 s duration trains of brief (5 ms) current pulses delivered at 0.5-20 Hz and adjusted in strength (ϳ250 pA) to produce a spike by 100% of the pulses delivered at 5 Hz in control conditions.
To simulate the effect of the noisy orexin current on firing, two approaches were used. In the first approach, a previously recorded inward orexin current (holding potential of Ϫ65 mV) was scaled and used as the command current in current-clamp recording experiments. In the second approach, a noisy orexin conductance was added by dynamic clamp, which was implemented using QuB software as modified by Dr. Lorin S. Milescu (Milescu et al., 2008) , running on a PC (ASL, Marquis M517-T) controlling a National Instruments multifunction PCIe card (NI PCIe-6251). The virtual orexin conductance was derived from a typical orexin current recorded at Ϫ65 mV from a DR neuron having an average conductance of 0.5 nS and an estimated reversal potential of Ϫ15 mV. The normalized conductance fluctuations were computed from the current fluctuations divided by the driving force and were well fit with a Gaussian function having a mean of 1.0 and a SD of 0.183. The virtual orexin current injected by the dynamic clamp was determined by the equation I orx ϭ G ave ϫ G fluct ϫ (V m Ϫ V rev ), where G ave ranged between 0.5 and 2 nS, G fluct is the normalized conductance wave, V m is the membrane potential, and V rev is the orexin reversal potential (Ϫ15 mV).
To uncage IP3 inside recorded neurons, D-myo-inositol 1,4,5-trisphosphate, P4(5)-(1-(2-nitrophenyl)ethyl) ester, tris(triethylammonium) salt (NPE-Caged Ins 1,4,5-P3; Invitrogen) was dissolved in normal patch pipette solution to a final concentration of 100 M. To uncage Ca 2ϩ inside recorded neurons, 2 mM DMNP-EDTA (1-(4,5-dimethoxy-2-nitrophenyl)-1,2-diaminoethane-N,N,NЈ,NЈ-tetraac-etic acid, ThermoFisher, D6814; DMNP) with 0.75 mM CaCl 2 was dissolved in normal patch solution containing 100 M Oregon Green BAPTA 2. Using Patcher's Power Tools (version 2.19) XOP (http:// www3.mpibpc.mpg.de/groups/neher/index.php?pageϭaboutppt) for Igor Pro 6 (Wavemetrics, RRID:SCR_000325), we estimated a resting free Ca 2ϩ concentration of ϳ70 nM. Both solutions were prepared in low light, and patching was done using IR illumination. Neurons were filled for Ͼ5 min before experiments began. For caged IP3, photolysis was accomplished using flashes of 380 nm light provided by our xenon arc lamp with exposure time controlled by the shutter system. For caged Ca 2ϩ , photolysis was accomplished using a Prizmatix Mic-LED emitting at 385 nm (15 nm FWHM) with exposures determined by computergenerated TTL pulses gating the controller. To minimize uncaging within the pipette, the neuron was positioned so that the pipette was mostly occluded by the edge of the aperture in the light path. DMNP uncaging pulses were delivered at intervals of Ͼ2 min and were interleaved with three 5 pulse protocols.
Data analyses. Data were analyzed and figures prepared using Igor Pro 6. All reported values of V m have been corrected by Ϫ15 mV to compensate for liquid junction potentials, which were measured for each patch solution and ACSF combination (range: Ϫ14.7 to Ϫ16.4 mV). Action potential and AHP amplitudes were measured from the baseline membrane potential. R input was measured in current clamp with Ϫ10 or Ϫ20 pA pulses or in voltage clamp with Ϫ10 mV pulses. AHP duration was measured as time to 50% recovery (T 50 ). Spike-frequency adaptation (SFA) was determined from the initial (first interspike interval) and steady-state firing frequency (last 3-5 intervals) produced by 5 s current pulses. Curve fitting was done using Igor Pro. Single and double exponentials were fit to average currents to estimate time constants (tau). A Boltzmann function (1/(1 ϩ exp (V 1/2 Ϫ V m /k))) was fit to the average G/G max and I/I max curves measured for the transient outward current to determine V 1/2 and the slope factor, k. All fit coefficients are reported as the coefficient Ϯ the 95% confidence interval. Other results are reported as mean Ϯ SEM. Groups were compared using two-tailed t tests, ANOVAs, or repeated-measures ANOVAs (Data Desk 6 and 7, Data Description). Results from these tests are reported as the value of the t statistic or the F ratio with corresponding degrees of freedom in parentheses. Following a significant ANOVA, group differences were compared using Fisher's least significant difference post hoc tests. Significance was set at p Ͻ 0.05. To minimize variability from possible drifts in experimental conditions (e.g., different lots of orexin), treatment and control responses were obtained from interleaved recordings.
Immunofluorescence. To identify serotonergic neurons, slices were immersion fixed (4% PFA) overnight and cryoprotected (30% sucrose in PBS). Slices were then resectioned (40 m) on a freezing microtome, and free-floating sections were immunolabeled with antibodies against tryptophan hydroxylase (TpH; Abcam, 3907, RRID:AB_304147; and Covance PSH-327P, RRID:AB_10063449, sheep polyclonals, 1:400). Serotonergic neurons were identified by immunofluorescence using an Alexa-488-conjugated secondary antibody (Invitrogen, A11015, donkey anti-sheep).
Results
Large neurons (long axis Ͼ ϳ25 m) in the dorsal and ventromedial portions of the DR nucleus were chosen for recording (n ϭ 292) and had an average input resistance of 670.2 Ϯ 38.9 M⍀ (n ϭ 44), which is comparable with previous measurements (e.g., Rood et al., 2014) .
Orexin enhances the late AHP
Orexin-A (300 nM) application produced membrane depolarization, a clearly discernible increase in membrane potential noise and firing. To examine the AHP, we repolarized the neurons (Fig. 1A , ϪI inj ) to baseline with DC current and then compared the AHP produced by the 5 spike protocol (Fig. 1A , right blue box) to that evoked before orexin-A (Fig. 1A, left, red box) . Superimposing the traces (Fig. 1A, right) revealed that, following orexin application, the peak of the AHP was larger (control: 6.6 Ϯ 0.5 mV; orexin: 12.7 Ϯ 1.4 mV, n ϭ 21; paired t test: t (20) ϭ 4.76, p Ͻ 0.05), later, and slower to recover (control T 50 : 0.62 Ϯ 0.06 s; orexin T 50 : 2.2 Ϯ 0.24 s, n ϭ 21; paired t test: t (20) ϭ Ϫ7.16, p Ͻ 0.05). Of the 22 DR neurons studied in this way, one did not show this AHP effect. Thirteen neurons that showed this oeAHP were recovered after recording, and 12 of 13 were TpHimmunopositive (Fig. 1B) . Moreover, an oeAHP was observed in all cells for which orexin produced a depolarization. It was activated over the same orexin dose range (Fig. 1C) and developed over the same time course (Fig. 1D ) as the depolarization.
Previous studies showed that adrenergic ␣-1 receptor activation increases the AHP in DR neurons (Freedman and Aghajanian, 1987; Pan et al., 1994) ; and because orexins can release norepinephrine (Hirota et al., 2001) , we tested whether the oe-AHP might result from indirect activation of ␣-1 receptors. We confirmed that the ␣-1 agonist PE (300 nM to 30 M) depolarized and enhanced the AHP in mouse DR neurons (3 M PE, AHP amplitude: 139.0 Ϯ 17.0% of control; AHP duration: 315.4 Ϯ 63.9% of control, n ϭ 5) but found that prasozin (100 nM), which completely blocked the PE effects, failed to block the oeAHP (n ϭ 11; Fig. 1E ). Nevertheless, PE (3 M) enhancement of the AHP was sufficient to occlude any further enhancement by orexin-A (300 nM; AHP amplitude in orexin: 102.1 Ϯ 3.8% of AHP in PE, paired t test: t (4) ϭ 0.54, p Ͼ 0.05; AHP duration in orexin: 94.4 Ϯ 9.3% of AHP in PE; paired t test: t (4) ϭ Ϫ1.57, p Ͼ 0.05, n ϭ 5; Figure 1F ).
Because there are sex differences in 5-HT DR neurons and baseline firing rates are higher in male rats (Klink et al., 2002) , we examined whether we could detect a sex difference in the late AHP or in the oeAHP. The control AHPs evoked with the 5 spike protocol were not different in either amplitude (male: 7.22 Ϯ 0.79 mV, n ϭ 11; female: 5.66 Ϯ 0.75 mV, n ϭ 7; unpaired t test: t (16) ϭ Ϫ1.35, p ϭ 0.19) or in T 50 (male: 0.56 Ϯ 0.06 s, n ϭ 11; female: 0.68 Ϯ 0.15 s, n ϭ 7; unpaired t test: t (16) ϭ Ϫ0.83, p ϭ 0.42). Moreover, orexin-A (300 nM) strongly increased the amplitude and duration of the late AHP in slices from both sexes, with a trend toward larger increases in slices from females. Nevertheless, no statistically significant difference between males and females was found in either the amplitude increase (male: 155.5 Ϯ 19.4%, n ϭ 11; female: 222.8 Ϯ 39.2%, n ϭ 7; unpaired t test: t (16) ϭ 0.17, p Ͼ 0.05) or duration increase (male: 385.0 Ϯ 69.1%, n ϭ 11; female: 459.0 Ϯ 90.9%, n ϭ 7; unpaired t test:
Either OxR alone can mediate the oeAHP in DR neurons
Because mRNA for both OX 1 and OX 2 is expressed in the DR (Trivedi et al., 1998; Marcus et al., 2001) , and either receptor is sufficient to produce the orexin-mediated inward current (Kohlmeier et al., 2013) , we tested whether each receptor was competent to produce the oeAHP using slices from mice lacking one receptor. Application of 300 nM orexin-A evoked a depolarization and an unambiguous oeAHP in DR neurons recorded in slices from OX 1 Ϫ/Ϫ ( Fig. 2A) and OX 2 Ϫ/Ϫ (Fig. 2B ) mice. Moreover, neither the increase in AHP amplitude (OX 1 Ϫ/Ϫ : 165.6 Ϯ 23.4%, n ϭ 5; OX 2 Ϫ/Ϫ : 152.1 Ϯ 24.2%, n ϭ 5) nor increase in AHP duration (OX 1 Ϫ/Ϫ : 345.1 Ϯ 98.6%, n ϭ 5; OX 2 Ϫ/Ϫ : 322.8 Ϯ 63.2%, n ϭ 5) was different from those recorded in control DR neurons (amplitude: 194.2 Ϯ 18.4%, n ϭ 21; duration: 416.1 Ϯ 49.9%, n ϭ 21) in slices from C57BL6 mice ( Fig. 2C ; Amplitude, ANOVA: F (2,28) ϭ 0.76, p Ͼ 0.05; Duration, ANOVA: F (2,28) ϭ 0.50, p Ͼ 0.05). To confirm that these OxRs were, indeed, neces-sary, we also recorded DR neurons in slices from DKO mice (n ϭ 5 from 3 DKO mice). Orexin-A (300 nM) produced neither a depolarization nor a change in the AHP (Fig. 2D , top traces; amplitude: 97.9 Ϯ 5.6% of control, n ϭ 5; duration: 99.66 Ϯ 2.6% of control, n ϭ 5), although application of PE still produced an increase in amplitude and duration of the AHP in these neurons (Fig. 2D , bottom traces). Thus, both OX 1 and OX 2 are competent to mediate the oeAHP in DR neurons.
This suggests that orexin could produce an oeAHP in neurons normally expressing predominantly OX 1 or OX 2 receptors. To test this idea, and to determine whether neurons other than DR neurons expressed this type of orexin action, we examined the effect of orexin-A on the late AHP of two other arousal-linked targets: the TMN, where the orexin-mediated depolarization is primarily mediated by OX 2 (Eriksson et al., 2001; Willie et al., 2003) ; and the LDT, where the orexin-mediated depolarization is primarily mediated by OX 1 (Kohlmeier et al., 2013) . We found orexin-A (300 nM) enhanced the AHP duration evoked with the 5 spike protocol in TMN neurons (control: 0.6 Ϯ 0.18 s; orexin: 1.05 Ϯ 0.11 s, n ϭ 3 of 3; paired t test: t (2) ϭ Ϫ3.03, p Ͻ 0.05; Fig. 2E ) and in LDT neurons (control: 0.56 Ϯ 0.12 s; orexin: 2.06 Ϯ 0.83 s, n ϭ 7/11; paired t test: t (6) ϭ 1.14, p Ͻ 0.05; Fig. 2F ). However, unlike in the DR, the average amplitude of the late AHP was not increased in TMN neurons (control: 5.0 Ϯ 0.8 mV; orexin: 5.0 Ϯ 1.0 mV, n ϭ 3 of 3; paired t test: t (2) ϭ Ϫ0.04, p Ͼ 0.05) or LDT neurons (control: 6.8 Ϯ 1.4 mV; orexin: 9.0 Ϯ 1.8 mV, n ϭ 7 of 11; paired t test: t (6) ϭ Ϫ1.99, p Ͼ 0.05), suggesting that different mechanisms may be involved. Nevertheless, this indicates that the AHP enhancing action of orexin is not restricted to DR neurons and can be observed in neuronal populations naturally expressing a predominance of either receptor. . The mean Ϯ SEM AHP parameters time to AHP peak (Peak), AHP amplitude (Amp), and duration of the AHP to 50% recovery (50% Rec) are shown with changes in input resistance (Rin) and the current injected to keep membrane potential at baseline (I inj ). E, An average of three 5 spike-evoked AHPs before (Control, red) and after (Orx A, blue) orexin-A (300 nM) in ACSF containing prazosin (100 nM). F, The 5 spike-evoked AHP before (Control, red), during PE (3 M, green) and during PE ϩ orexin-A (300 nM, PE ϩ Orx A, blue). Scale bars in E apply to F. (Fig. 3A, top traces) or the 5 spike protocol (Fig. 3A , bottom traces) were readily detected and orexin enhanced the AHP following both stimuli. However, orexin did not increase the average somatic Ca 2ϩ transient produced by single spikes (orexin: 92.6 Ϯ 3.1% of control, n ϭ 7) or by 5 spikes (orexin: 96.7 Ϯ 10.0% of control, n ϭ 20; Fig. 3B ).
To determine whether elevation of intracellular [Ca 2ϩ ] was necessary for the oeAHP, we recorded with a patch solution containing the fast calcium buffer BAPTA (10 mM). Under these conditions, the late AHP following 1 and 5 spikes was undetectable ( Fig. 3C) , even though recording conditions remained excellent, as indicated by normal input resistance and action potential amplitude (Fig. 3C, inset) . Moreover, despite an intact orexinevoked depolarization and large increase in membrane noise (data not shown), no enhanced AHP following 1 or 5 spikes emerged following the application of orexin. This indicates that the AHP enhanced by orexin requires elevation of intracellular Ca 2ϩ and did not result from a Ca 2ϩ -independent current that was switched on by OxR activation.
Using a normal internal solution, we next applied ACSF having Co 2ϩ substituted for Ca 2ϩ to block voltage-gated Ca 2ϩ channels and thus determine whether Ca 2ϩ influx was necessary for the oeAHP. Switching into this ACSF completely blocked the late AHP following either 1 or 5 spikes (Fig. 3D) . Again, despite an intact orexin-evoked depolarization and a large increase in membrane noise, neither 1 nor 5 spikes elicited an oeAHP following orexin application (n ϭ 5), even though recording conditions remained excellent and action potentials retained their normal amplitude (Fig. 3D, inset) . Moreover, enabling Ca 2ϩ influx by reintroducing normal Ca 2ϩ ACSF greatly prolonged the late AHP compared with control, even though the orexin action was subsiding, as indicated by a recovering inward current. Thus, the oeAHP requires Ca 2ϩ influx and elevation of intracellular Ca 2ϩ .
Orexin enhances an apamin-sensitive K ؉ current and a slower apamin-insensitive current that is insensitive to UCL2077 We next conducted voltage-clamp recordings to measure the oe-AHP current (I oeAHP ). Following spike blockade with TTX, AHP currents were evoked using the 5 pulse protocol delivered every 30 s before and after orexin-A application (300 nM; Fig. 4A ). As the noisy inward orexin current developed, a prolonged AHP current emerged ( Fig. 4B ; compare top traces). Subtracting these currents, following leak-correction, yielded the I oeAHP (Fig. 4B , bottom trace), which decays more slowly than the AHP current in control condition and underlies the oeAHP observed in currentclamp experiments.
To estimate the reversal potential of this current, we measured the instantaneous current-voltage curve resulting from brief voltage steps timed to occur at the peak of I oeAHP , and delivered both with and without a preceding 5 pulse protocol (Fig. 4C, inset) . These curves crossed between Ϫ95 and Ϫ100 mV ( Fig. 4D ; n ϭ 7) near the computed E K (Ϫ86 mV, dashed line). Shifting E K by ϳ18 mV with ACSF containing either 2.5 or 10 mM K ϩ shifted this estimated reversal potential by Ϫ24 mV (n ϭ 4) and 19 mV (n ϭ 5), respectively (data not shown), indicating K ϩ channel involvement in I oeAHP . The Ca 2ϩ dependence and shift in reversal with E K suggest involvement of Ca 2ϩ -activated K ϩ channels. Two slow Ca 2ϩ -dependent K ϩ currents with different kinetics commonly mediate a medium (I mAHP ) and slow AHP (sAHP, I sAHP ) in neurons. Channels mediating I mAHP are mostly blocked by apamin, a selective blocker of channels containing SK1-3 subunits (for review, see Stocker et al., 2004) . In contrast, the I sAHP is strongly inhibited by some neurotransmitters, but the underlying channels are generally unidentified, often insensitive to channel blockers and may be different in different neurons (Vogalis et al., 2003) . To test for SK channel involvement, we applied apamin, which blocks most of the postspike AHP in control condition and the AHP enhancement produced by PE (Freedman and Aghajanian, 1987; Pan et al., 1994) . Following pretreatment with apamin (100 or 300 nM), our control AHP was blocked by ϳ90% (100 nM: 88% blocked, n ϭ 11, paired t test: t (10) ϭ 11.98, p Ͻ 0.05; 300 nM: 91% blocked, n ϭ 12, paired t test: t (11) ϭ 6.34, p Ͻ 0.05), yet after orexin, I oeAHP amplitude (18.7 Ϯ 1.9 pA, n ϭ 23) was only reduced by approximately half (45.0% of control amplitude: 41.5 Ϯ 3.4 pA; n ϭ 11; unpaired t test: t (32) ϭ Ϫ6.34, p Ͻ 0.05; Fig. 4E ). This indicates that both an apamin-sensitive SK Figure 2 . Activation of either OxR alone produces the oeAHP. A, B, An average of three 5 spike-evoked AHPs before (Control, red) and after orexin-A (300 nM; Orx A, blue) in DR neurons recorded in slices from OX 1 null mice (A) and OX 2 null mice (B). C, The effects of orexin-A (300 nM; mean percentage of Control Ϯ SEM) on the amplitude (Amp) and duration (50% recov) of the 5 spike-evoked AHP. D, An average of three 5 spike-evoked AHPs before (red) and after orexin-A (300 nM; blue) in a DR neuron from a DKO mouse (top traces). An average of three 5 spike-evoked AHPs before (Control, red) and after PE (10 M; lower traces, PE, green) in a DR neuron from a DKO mouse. E, F, An average of three 5 spike-evoked AHPs before (red) and after orexin-A (300 nM; blue) in a TMN neuron (E) and a LDT neuron (F ). All scale bars correspond to those in A.
current (I SK ) and an apamin-insensitive current are involved. Involvement of two currents was also suggested by the oftenobserved biphasic decay kinetics of I oeAHP . To estimate the time course of each component, we averaged I oeAHP from control (n ϭ 7) and apamin pretreated (n ϭ 7) recordings. In the control average, the decay was well fit by a medium (tau ϭ 0.8 Ϯ 0.08 s) and slow exponential (tau ϭ 6.0 Ϯ 0.02 s; Fig. 4F , top). In the apamin average, the decay was well fit by a single slow exponential (tau ϭ 5.9 Ϯ 0.01 s; Fig. 4F , second trace). This suggests that the oeAHP results from both an increase in the medium-duration I SK present before orexin application and the emergence of a longer-duration apamin-insensitive current that was absent before orexin application. We confirmed the presence of this enhanced I SK by applying apamin (300 nM) just after emergence of the orexin effect and subtracting the apamin-insensitive component from the initial orexin-enhanced current, to yield the I SK in orexin. From this, we then subtracted the SK current before orexin, to yield the orexin-enhanced SK current (I oeSK ). The averaged I oeSK (n ϭ 6) was well fit with a single exponential having a medium decay (tau ϭ 0.71 Ϯ 0.01 s; Fig. 4F, third trace) .
The apamin-insensitive part might be mediated by an I sAHP , which is found in many types of neurons. The antiepileptic compound UCL2077, which blocks KCNQ1/2 channels (Soh and Tzingounis, 2010), has recently been found to inhibit the classical I sAHP in hippocampal pyramidal neurons (Shah et al., 2006) and in paraventricular thalamic (PVT) neurons, where orexin inhibits I sAHP (Zhang et al., 2010) . We therefore tested whether UCL2077 blocks the oeAHP current in DR neurons. Following preapplication of UCL2077 (10 M, Ͼ7 min), the oeAHP current was still biphasic (medium tau ϭ 1.2 Ϯ 0.03 s; slow tau ϭ 6.5 Ϯ 0.08 s; Fig. 4F , fourth trace) and had an average amplitude of 29.4 Ϯ 6.4 pA (n ϭ 4), which was not significantly different from that in control ACSF (p Ͼ 0.05), indicating that the slow part of the oeAHP is resistant to UCL2077 and is mediated by different channels from those mediating the sAHP in hippocampus and PVT neurons.
PLC antagonism blocks the entire I oeAHP and the orexin-mediated inward current, but these currents do not require PKC activation and are insensitive to altered cAMP/PKA signaling Both OX 1 and OX 2 can activate PLC, although it has become apparent that these receptors can also couple to other second-messenger systems (Kukkonen and Leonard, 2014). We therefore examined whether intracellular application of U73122, an inhibitor of PLC, could inhibit the oeAHP. As control, we first evaluated the inactive analog U73343 (1 M) on both the orexin currents and the outward current activated by 5-HT because the latter current does not depend on PLC activation (Innis et al., 1988; Williams et al., 1988; Penington et al., 1993) . Under these conditions, orexin and 5-HT produced their expected actions (n ϭ 5; Fig. 5A ), whereas the active analog U73122 (n ϭ 6) blocked both the orexin-mediated inward current and the entire I oeAHP ,without reducing the 5-HT current (Fig. 5B) . Results from ANOVAs (inward current: F (2,19) ϭ 6.61, p Ͻ 0.05; I oeAHP : F (2,19) ϭ 5.70, p Ͻ 0.05) followed by post hoc testing confirmed that the orexin action was not different from control in recordings with the inactive analog but was blocked in recordings with the active analog ( post hoc tests, p Ͻ 0.05; Fig.  5C ). In contrast, the active analog did not attenuate the outward current evoked by 5-HT (unpaired t test, t (9) ϭ 0.90, p Ͼ 0.05, compared with inactive analog; Fig. 5D ). Thus, the PLC inhibitor U73122 selectively blocked both the orexin-mediated inward current and the I oeAHP .
Neurotransmitter inhibition of the classical I sAHP is mediated by both cAMP/PKA signaling (Pedarzani and Storm, 1993) and activation of PLC (Villalobos et al., 2011) , with involvement of PKC in some cases (Malenka et al., 1986; Agopyan and Agopyan, 1991). Indeed, whereas the I sAHP in PVT neurons is inhibited by both PKA and PKC activation, orexin-mediated inhibition of the I sAHP was only blocked by PKC inhibitors (Zhang et al., 2010) . We therefore tested whether the oeAHP might also involve these signaling pathways. In the first series of experiments, we tested whether PKCIP (2 M in the patch solution, dialyzed for Ͼ10 min) (Hall et al., 1995; Schubert et al., 1999) or the PKC inhibitor Bis I (1 M, brain slices preincubated for Ͼ45 min) altered I oeAHP . Before orexin application, the AHP current produced by the 5 pulse protocol was 67.4 Ϯ 14.8 pA with the PKCIP (n ϭ 4) and 60.4 Ϯ 9.1 pA with Bis I (n ϭ 7). Neither of these was different from the control AHP current (87.4 Ϯ 7.5 pA, n ϭ 11; ANOVA: F (2,19) ϭ 2.64, p Ͼ 0.05). Application of orexin-A (300 nM) resulted in an I oeAHP of 36.1 Ϯ 2.5 pA with the PKCIP (Fig. 5F ; n ϭ 4) and an I oeAHP of 29.6 Ϯ 5.6 pA with Bis I (Fig. 5G ; n ϭ 7). Neither was different from the I oeAHP measured in corresponding control experiments (41.5 Ϯ 3.4 pA, n ϭ 11; Fig.  5E ), suggesting that PKC activation is not required for triggering the oeAHP. In contrast, the PKC activator PDBu (1 M, n ϭ 6) strongly reduced the I oeAHP (4.1 Ϯ 2.0 pA; Fig. 5H ) compared with control or PKC inhibitor conditions ( Fig. 5J ; ANOVA: F (3,24) ϭ 9.70, p Ͻ 0.05), suggesting that PKC, when activated, can inhibit the expression of I oeAHP .
In the second series of experiments, we examined involvement of the cAMP/PKA pathway in regulating the late AHP and I oeAHP by applying forskolin (10 M; Ͼ10 min) before orexin application. The average amplitude of the late AHP current produced by the 5 pulse protocol before forskolin application was 125.5 Ϯ 17.1 pA, and it was unchanged by forskolin application (122.1 Ϯ 18.5 pA, paired t test: t (4) ϭ 0.90, p Ͼ 0.05, n ϭ 5). Following orexin application with forskolin (300 nM, n ϭ 5), the I oeAHP was still observed (38.6 Ϯ 8.5 pA; Fig. 5I ), and it was not different in amplitude from I oeAHP produced without forskolin (unpaired t test: t (14) ϭ 0.39, p Ͼ 0.05; Fig. 5E ). Thus, unlike neurotransmitter inhibition of the classical I sAHP , I oeAHP in DR neurons does not appear to depend on PKC activation or the cAMP/PKA system. (Bildl et al., 2004; Allen et al., 2007) . Because SK2 deactivation kinetics are slowed by PP2A-mediated dephosphorylation, we intracellularly applied an inhibitor of PP2A (okadaic acid; 25 nM; Ͼ12 min) to determine whether this would shorten the I SK in DR neurons and perhaps prevent the early, apamin-sensitive part of the oeAHP Figure 4 . The oeAHP current (I oeAHP ) reverses near the potassium equilibrium potential (E K ) and has a biphasic decay mediated by a medium duration SK current and a slower apamin-insensitive current. A, Continuous recording of membrane current in voltage-clamp mode (holding potential Ϫ65 mV) before and during application of orexin-A (Orx A, 300 nM). Intermittent 5 pulse protocols (delivered ϳ30 s intervals) evoked AHP currents before (left, red dashed box) and after Orx A (right, blue dashed box). B, Top traces, Leak-corrected currents from A before (red) and after (blue) Orx A (3 traces averaged). Bottom trace (purple), I oeAHP , computed as the difference between the top traces. C, Membrane current in orexin (magenta) is superimposed on the membrane current evoked by the 5 pulse protocol (blue) in orexin. Brief (20 ms) voltage pulses (Ϫ115 mV to Ϫ55 mV in 10 mV increments, bottom black trace, inset) were delivered during both traces at a time corresponding to the peak of the oeAHP (bar). The current at the end of each brief step (top traces, inset) was used to estimate the instantaneous I-V relation. D, Resulting instantaneous current (mean Ϯ SEM, Im)-voltage (V m ) relations for traces without the 5 pulse protocol (Ϫ prepulses, open squares, magenta) and traces with the 5 pulse protocol (ϩ prepulses, filled squares, blue) cross near the calculated potassium reversal potential (E K ; n ϭ 7). E, Apamin (100, 300 nM) reduced the amplitude (mean Ϯ SEM) of I oeAHP (n ϭ 23). *p Ͻ 0.05. F, The average I oeAHP (purple) under control conditions (n ϭ 7; top) had a biphasic decay that was well fit with the sum of a medium and slow-decaying exponential (superimposed white trace). The average I oeAHP in apamin (n ϭ 7; second trace) decayed with a single slow exponential (superimposed white trace). The average orexin-enhanced SK current (I oeSK , n ϭ 5; third trace) was well fit with a mediumdecaying single exponential (superimposed white trace). The average I oeAHP in UCL2077 (n ϭ 4; fourth trace) also had a biphasic decay that was well fit with the sum of a medium and slow-decaying exponential (superimposed white trace).
Ca
current. Recordings with okadaic acid in the pipette revealed a baseline AHP current with a magnitude (76.4 Ϯ 13.5 pA, n ϭ 7), similar to that observed with normal pipette solution (87.4 Ϯ 7.5 pA, n ϭ 11, unpaired t test: t (16) ϭ 0.77, p Ͼ 0.05), but with a duration (T 50 : 0.42 Ϯ 0.03 s) that was shorter than that with normal pipette solution (T 50 : 0.66 Ϯ 0.08 s; unpaired t test: t (16) ϭ 2.33, p Ͻ 0.05), consistent with PP2A inhibition and greater SK phosphorylation. However, I oeAHP recorded under these conditions still showed a biphasic decay with an amplitude (48.5 Ϯ 5.1 pA, n ϭ 7) that was not different from control (unpaired t test: t (16) ϭ Ϫ1.17, p Ͼ 0.05; Fig. 6A ). This indicates that I oeAHP was resistant to PP2A inhibition and that prolongation of the SK current by orexin occurred independently of PP2A-mediated dephosphorylation.
Because I oeAHP depends on PLC, but not on PKC activation, we next examined whether it might depend on Ca 2ϩ release from intracellular stores, which could result from PLC-mediated production of IP3. We first applied the sarco/endoplasmic reticulum Figure 5 . PLC inhibitor U73122 blocked both the orexin-induced inward current and I oeAHP , although both currents were resistant to PKC inhibitors and forskolin despite being abolished by PDBu. A1, Continuous membrane current with intermittent 5 pulse protocols (holding potential ϭ Ϫ65 mV) recorded with U73343 (1 M, inactive analog of U73122) in the pipette before and after application of Orx A (300 nM; left) or serotonin (5-HT; 30 M; right). A2, I oeAHP (purple) computed from recordings in A1. B1, Membrane current with intermittent 5 pulse protocols (holding potential ϭ Ϫ65 mV) recorded with U73122 (1 M, selective PLC inhibitor) in the pipette before and after application of Orx A (300 nM; left) or serotonin (5-HT; 30 M; right). B2, I oeAHP (purple) computed from recordings in B1 was completely abolished. C, Summary (mean Ϯ SEM) of currents produced by orexin recorded with either U73343 (n ϭ 5) or U73122 (n ϭ 6) in the pipette. U73122 strongly attenuated the inward current and I oeAHP . *p Ͻ 0.05. D, Summary (mean Ϯ SEM) of outward current evoked by 5-HT in recordings with U73343 (n ϭ 5) and U73122 (n ϭ 6). ns, Not significant. E-I, Examples of I oeAHP computed for orexin application (300 nM) recorded under different conditions, including control (E), with the PKCIP in the pipette solution (F ), following slice preincubation with the PKC inhibitor Bis I (G), following application of the PKC activator PDBu (H ), and following preincubation with the adenylyl cyclase activator forskolin (Forsk) (I ). J, Summary of drug actions on the amplitude of I oeAHP (mean Ϯ SEM). **p Ͻ 0.05, significant comparisons from post hoc Fischer tests following a significant ANOVA, revealing differences between control and PKC drug groups.
2ϩ -ATPase (SERCA) inhibitor CPA (10 M, 10 min) to deplete intracellular Ca 2ϩ stores in these neurons (Kohlmeier et al., 2004) . In a series of current-clamp experiments, we found that CPA did not significantly change the amplitude of the SKmediated AHP evoked by the 5 spike protocol (Pre-CPA: 7.8 Ϯ 0.8 mV, CPA: 6.6 Ϯ 0.4 mV, n ϭ 5, paired t test: t (4) ϭ Ϫ2.43, p Ͼ 0.05), but it did significantly slow its recovery (Pre-CPA T 50 : 0.7 Ϯ 0.1 s, CPA T 50 : 1.2 Ϯ 0.1 s, n ϭ 5, paired t test: t (4) ϭ Ϫ6.15, p Ͻ 0.05). This suggests that SERCA-dependent Ca 2ϩ sequestration normally contributes to recovery of the SK-mediated AHP. Following Ca 2ϩ -store depletion with CPA, application of orexin-A (300 nM; Fig. 6B ) produced a membrane depolarization that appeared normal and an oeAHP that achieved the same duration as the oeAHP without CPA (oeAHP with CPA T 50 : 2.2 Ϯ 0.3 s, n ϭ 5; oeAHP no CPA T 50 : 2.2 Ϯ 0.24 s, n ϭ 21, unpaired t test: t (24) ϭ 0.14, p Ͼ 0.05). However in CPA, orexin-A application did not significantly increase the AHP amplitude (AHP in CPA: 6.6 Ϯ 0.4 mV; oeAHP in CPA: 8.1 Ϯ 1.2 mV, n ϭ 5, paired t test: t (4) ϭ 0.11, p Ͼ 0.05). We further tested this in series of voltage-clamp experiments where we found that the I oeAHP recorded in CPA (27.9 Ϯ 3.4 pA, n ϭ 7; Fig. 6D ) was smaller than that in control conditions but was similar in amplitude to that in apamin alone and in CPA following preblocking SK channels with apamin (19.7 Ϯ 2.9 pA, n ϭ 5). A significant ANOVA (F (3,42) ϭ 11.10, p Ͻ 0.05) followed by post hoc testing confirmed that the I oeAHP in CPA was significantly smaller than in Control ( p Ͻ 0.05) but was not different from the I oeAHP recorded in apamin ( p Ͼ 0.05) or in CPA with apamin ( p Ͼ 0.05). These data indicate that store release is necessary for the orexin-mediated enhancement of the apamin-sensitive component, but not for the longer-lasting apamin-insensitive component of I oeAHP .
We next examined whether store involvement was mediated by IP3 receptors (IP3Rs) and/or ryanodine receptors (RyRs). Intracellular application of the IP3R antagonists XeC (1 M) or 2-APB (50 M) did not reduce I oeAHP (XeC: 47.0 Ϯ 9.2 pA, n ϭ 6; 2-APB: 52.6 Ϯ 13.7 pA, n ϭ 6; Fig. 6 E, F ) . In contrast, I oeAHP was smaller in recordings obtained with the RyR antagonist RuR (100 M) in the patch solution (RuR: 23.3 Ϯ 2.9 pA, n ϭ 7; Fig. 6 E, F ) , and this was not further reduced by preblocking SK channels with apamin (21.9 Ϯ 4.9 pA, n ϭ 5; Fig. 6F ). An ANOVA (F (4,34) ϭ 4.45, p Ͻ 0.05) with post hoc testing of these data, following a log-transform to correct for heterogeneity of variance across recording groups, confirmed that I oeAHP amplitude was not different from control ( p Ͼ 0.05) in recordings with XeC or 2-APB but was smaller than control in recordings with RuR and RuR with apamin pretreatment ( p Ͻ 0.05). Moreover, when recorded with RuR, I oeAHP was not different in amplitude from that recorded in apamin alone (unpaired t test: t (28) ϭ 1.23, p Ͼ 0.05), and the average decay was well fit by a single exponential (tau ϭ 2.6 Ϯ 0.01 s, n ϭ 7). In addition, apamin pretreatment did not further reduce I oeAHP recorded with RuR. These data suggest that the Ca 2ϩ release underlying I SK enhancement requires RyRs but does not require IP3R activation. This conclusion is tempered by potential off-target actions of these drugs (e.g., see Taylor and Broad, 1998) ; so to directly test IP3 involvement, we recorded from DR neurons with a patch solution containing caged-IP3 and used full-field UV flashes (500 ms) to release IP3 into the cytoplasm. Uncaging IP3 failed to induce a membrane current in DR neurons either before or after application of orexin (Fig. 6G, left  traces) , even though the 5 pulse protocol produced an AHP current that was greatly enhanced by orexin in the same neurons (Fig. 6G, right traces) . Similarly, when uncaging was paired with the 5 pulse protocol (500 ms UV pulse started simultaneously with the first depolarization), I oeAHP was not altered (paired with UV amplitude 101.2 Ϯ 6.4% of that without UV, n ϭ 5, paired t test: t (4) ϭ Ϫ0.70, p Ͼ 0.05). To verify that we were successfully uncaging IP3, we conducted identical recordings from hippocampal CA1 pyramidal neurons, where UV flashes produced an outward current (Fig. 6H ), as expected from previous studies showing perisomatic IP3 uncaging and ensuing Ca 2ϩ release activates SK channels (Hong et al., 2007; El-Hassar et al., 2011) . These results are summarized in Figure 6I . Collectively, these data indicate that enhancement of the SK component of the oeAHP involves activation of ryanodine receptors and Ca 2ϩ release from intracellular stores, presumably via CICR, but that activation of IP3Rs are not necessary or sufficient.
Orexin prolongs the SK component of I oeAHP via inhibition of A-current and a resulting increase in local Ca
2؉ influx SK channel gating is determined by the subplasma membrane elevation in Ca 2ϩ , which is not effectively detected by our bulk cytoplasmic somatic Ca 2ϩ indicator signals. We therefore reexamined the possibility that orexin increased spike-evoked Ca 2ϩ influx. We first measured the action potential width and found that orexin-A (300 nM) significantly broadened the spike (measured at Ϫ25 mV) to 109.0 Ϯ 2.0% of control (paired t test: t (17) ϭ 1.74, p Ͻ 0.05; Fig. 7A ). We also recorded action potentials with high intracellular BAPTA (10 mM) to block possible Ca 2ϩ -dependent K ϩ repolarization currents and found that orexin-A broadened the spike by 111.5 Ϯ 4.2% of control (paired t test: t (7) ϭ 2.34, p Ͻ 0.05). Similarly, in voltage-clamp mode, we found that the poorly clamped Ca 2ϩ action currents (CACs), evoked by our voltage-steps, were also augmented by orexin (Fig. 7B) . These orexin effects could result from increasing voltage-gated Ca 2ϩ currents or reducing spike-repolarization currents. We therefore first examined the effect of orexin-A on isolated voltage-gated Ca 2ϩ currents. We monitored the leak-subtracted Ca 2ϩ currents evoked with 30 ms voltage steps from Ϫ65 mV to Ϫ25 mV. This protocol was delivered every 30 s before and after orexin-A (300 nM) application. This current was relatively stable, although both the peak inward current and tail current showed a slight run-down over the course of the recordings. Nevertheless, the current was not detectably altered by orexin application (Fig. 7C,D) .
We next examined whether orexin suppressed voltagedependent K ϩ currents. We isolated K ϩ currents and compared the effect of orexin-A (300 nM) on both the noninactivating and inactivating components in the same neurons. Orexin application did not change the delayed rectifier currents, but it reduced the transient outward current by ϳ20% (Fig. 8A-E) . Fitting the normalized activation and inactivation curves with Boltzmann functions revealed that the corresponding V 1/2 and slope factors (k) were similar before and after orexin (activation before orexin V 1/2 : Ϫ30.7 Ϯ 1.9 mV, k: 8.5 Ϯ 1.7; activation after orexin V 1/2 : Ϫ32.2 Ϯ 1.7 mV, k: 8.0 Ϯ 1.5; inactivation before orexin V 1/2 : Ϫ63.7 Ϯ 1.0 mV, k: Ϫ5.6 Ϯ 0.9; inactivation after orexin Figure 7 . Orexin-A broadened action potentials and CACs in DR neurons but did not increase isolated Ca 2ϩ currents. A, Action potentials were evoked by brief suprathrehold current pulses before (red, Con) and after orexin-A (blue, Orx, 300 nM). Three superimposed spikes recorded with normal patch solution and ACSF are shown for each condition. B, CACs recorded (voltage steps from Ϫ65 mV to Ϫ5 mV, 10 ms) with normal internal solution and ACSF containing TTX and synaptic blockers before (red, Con) and after application of orexin-A (blue, Orx, 300 nM). C, Pharmacologically isolated Ca 2ϩ currents were monitored by stepping V m from a holding potential of Ϫ65 mV to Ϫ25 mV for 30 ms every 30 s (Inset) before (red, Con) and orexin-A (blue, Orx, 300 nM). Superimposed Ca 2ϩ currents are from just before orexin-A application and following 2 min of orexin-A application. D, Summary of peak Ca 2ϩ current (mean Ϯ SEM) evoked as in C and measured before (Con) and after orexin application (Orx). The difference was not significant (paired t test, p Ͼ 0.05, n ϭ 5).
V 1/2 : Ϫ64.2 Ϯ 0.7 mV, k: Ϫ6.5 Ϯ 0.6), indicating that the transient current was reduced without changing voltage dependence ( Fig. 8C-E) . Because Co 2ϩ -ACSF was used to block voltagegated Ca 2ϩ channels in these recordings, these parameters will be somewhat shifted in the depolarizing direction (Mayer and Sugiyama, 1988) . From additional recordings in normal ACSF (data not shown), we estimate that the activation curve was positively shifted by ϳ10 mV, which fits well with previous estimates (Mayer and Sugiyama, 1988) and indicates this transient outward current activated below spike threshold. This, and the finding that the current was largely blocked by 5 mM 4-AP (Fig. 8F ) , which produced a characteristic late slowing of inactivation (Jackson and Bean, 2007) , indicates the current is a subthreshold A-current (Jerng et al., 2004) .
In addition to its well-known role in lengthening the interval between action potentials (Connor and Stevens, 1971), sub- Figure 8 . The enhanced SK component of I oeAHP results from orexin inhibition of A-current but not delayed rectifier current in DR neurons. A, Leak-subtracted (Ϫp/4) delayed rectifier currents before (left, red) and after (right, blue) application of orexin-A (300 nM; calibrations on right apply to both sets of current). Middle, Voltage protocol and holding potential. Calibration: Middle, 100 ms, 20 mV. B, Summary (mean Ϯ SEM) of the delayed rectifier current steady-state I-V relations before (open squares, red) and after (filled squares, blue) orexin (n ϭ 6). C, Leak-subtracted (Ϫp/4) transient outward currents evoked by the A-current activation protocol (middle traces; holding potential and calibration as in A) before (left, red) and after (right, blue) application of orexin-A (300 nM). D, Leak-subtracted (Ϫp/4) transient outward currents evoked by the A-current deinactivation protocol (middle traces; holding potential and calibration as in A) before (left, red) and after (right, blue) application of orexin-A (300 nM). E, Summary (mean Ϯ SEM) of the voltage dependence of activation and inactivation of the transient outward current before (open symbols, red) and after (filled symbols, blue) orexin application (n ϭ 6), normalized to the control I max and G max before orexin application. F, The transient outward current was monitored by depolarizing test pulses to Ϫ15 mV following a 75 ms hyperpolarizing conditioning pulse to Ϫ105 mV, showing characteristic blocking by 5 mM 4-AP. Three traces before 4-AP application (black) and three traces following the maximum blockade (red) are superimposed. G, CACs evoked by voltage steps to Ϫ5 mV (10 ms duration) from a holding potential of Ϫ65 mV from before (Con, black), during (4-AP, red) application of 5 mM 4-AP, and after application of orexin-A (300 nM; Orx, blue). H, SK currents evoked by the 5 pulse protocol (holding potential ϭ Ϫ65 mV) from before (Con, black) and after A-current blockade with 5 mM 4-AP (red). I, The average I oeAHP (n ϭ 8) produced by subsequent application of orexin-A (300 nM) in 5 mM 4-AP. The decay was well fit with a single slow exponential (white line). J, Outward currents produced by single full-field UV pulses (100 ms) to uncage Ca 2ϩ from DMNP before (red) and after (blue) application of orexin-A (300 nM). The holding current preceding each trace was subtracted. K, The average I oeAHP (n ϭ 5) computed from currents evoked by UV pulses (top, uvI oeAHP ) and from interleaved 5 pulse protocols (bottom, I oeAHP , 5 pulses). uvI oeAHP was well fit with a slow single exponential (white line on top trace) while the I oeAHP (5 pulses) was well fit with a double exponential having medium and slow time constants (white line on bottom trace). Calibration on bottom trace applies to both traces. L, Examples of SK current evoked by a UV pulse (uvI SK, UV, 100 ms, left traces) and a 5 pulse protocol (I SK , 5 pulses, right traces) from before (red) and after (blue) application of orexin-A (300 nM). Holding current preceding each trace was subtracted from each trace. Calibration on right applies to both sets of traces.
threshold A-currents also function in spike repolarization Yuan et al., 2005) , and this inhibition by orexin could therefore contribute to spike broadening, increased CACs, and an increase in the SK component of the oeAHP. Consistent with this idea, orexin (300 nM) produced significant broadening of action potentials measured with Ca 2ϩ channels blocked by Co 2ϩ -ACSF (spike width at Ϫ25 mV in orexin: 108.8 Ϯ 2.9% of control, paired t test: t (5) ϭ 2.57, p Ͻ 0.05; data not shown). To more directly test this idea, we applied 4-AP while measuring CACs and the AHP current. 4-AP (5 mM) enhanced the CACs (Fig. 8G ) and prolonged the SK-mediated AHP in the same cells ( Fig. 8H ; Control T 50 ϭ 0.48 Ϯ 0.07 s; 4-AP T 50 ϭ 0.58 Ϯ 0.09 s, n ϭ 8, paired t test: t (7) ϭ Ϫ2.13, p Ͻ 0.05). Treatment with 4-AP also occluded further enhancement of CACs by orexin-A (Fig.  8G ) and resulted in an I oeAHP whose amplitude was reduced by approximately half (18.2 Ϯ 2.7 pA, n ϭ 8; unpaired t test: t (17) ϭ Ϫ4.99, p Ͻ 0.05; Fig. 8I ) but was not different from that in apamin (unpaired t test: t (29) ϭ 0.14, p Ͼ 0.05). Moreover, the average I oeAHP in 4-AP decayed with a single component that was well fit by a single exponential ( Fig. 8I ; tau ϭ 4.7 Ϯ 0.03 s) like that in apamin. Collectively, these findings suggest that the augmented SK component of the oeAHP results from suppression of an A-current, broader action potentials and enhanced Ca 2ϩ influx, leading to an increase in subplasma membrane Ca 2ϩ , which is further enhanced by CICR. In contrast, the slower-decaying, apamin-insensitive component of the oeAHP was insensitive to A-current inhibition, indicating that a different Ca 2ϩ -dependent mechanism must be involved.
Because emerging evidence suggests that store filling can be modulated by intracellular signaling pathways (Yamasaki-Mann et al., 2010) , additional factors contributing to the augmented I SK might be that orexin enhances Ca 2ϩ sequestration, leading to greater store release in response to Ca 2ϩ influx, or that the Ca 2ϩ sensitivity of RyRs or SK channels is increased by orexin signaling. We reasoned that, if these factors are important, identical Ca 2ϩ transients should trigger enhanced I SK following orexin application. To bypass the orexin-enhanced CACs, we used fullfield DMNP Ca 2ϩ uncaging (100 -200 ms pulses) before and after orexin-A (300 nM) application and compared the evoked outward currents. We found that identical uncaging pulses produced a reproducible, medium-duration outward current before orexin that was blocked by apamin (300 nM; data not shown), and a more slowly decaying current following orexin application that was reminiscent of I oeAHP (Fig. 8J ) . The average outward current produced by Ca 2ϩ uncaging before orexin was 16.9 Ϯ 2.8 pA, whereas after orexin, the current was 25.0 Ϯ 3.6 pA (n ϭ 5). We computed I oeAHP resulting from uncaging pulses and found that this average current (uvI oeAHP ) was reasonably well fit by a single slow exponential (tau ϭ 4.70 Ϯ 0.012 s, n ϭ 5; Fig. 8K, top) , which was similar to the decay of I oeAHP in 4-AP (Fig. 8I ) . In contrast, the decay of I oeAHP produced by 5 pulses in these same neurons was well fit by a double exponential having medium (tau ϭ 0.36 Ϯ 0.004 s) and slow (tau ϭ 5.02 Ϯ 0.012 s) time constants (Fig. 8K, bottom) . Moreover, when we computed the total I SK evoked by UV after orexin, by applying apamin (300 nM) after orexin and then subtracting the apamin-insensitive component, we found that it was not any longer than I SK before orexin (T 50 before orexin ϭ 0.34 Ϯ 0.02 s; T 50 after orexin ϭ 0.30 Ϯ 0.03 s; t (4) ϭ 1.26, p Ͼ 0.05; Fig. 8L, left) . This differed from the I SK evoked by the 5 pulse protocol, tested in these same cells, which increased significantly in duration (T 50 before orexin ϭ 0.33 Ϯ 0.04 s; T 50 after orexin ϭ 0.44 Ϯ 0.05 s; t (4) ϭ Ϫ2.79, p Ͻ 0.05; Fig. 8L, right) . It is noteworthy that the prolongation of I SK by orexin obtained here, using patch solution with DMNP, agrees well with findings obtained using normal patch solution (I SK T 50 before orexin ϭ 0.35 Ϯ 0.05 s, T 50 after orexin ϭ 0.43 Ϯ 0.07 s; t (5) ϭ 3.28, p Ͻ 0.05; data not shown). Collectively, these findings suggest that in order for orexin to prolong the I SK and thereby produce the SK component of the I oeAHP , an enhanced Ca 2ϩ influx is required. Nevertheless, because DMNP alters intracellular Ca 2ϩ buffering, this conclusion should be considered tentative. Future experiments using a wider range of Ca 2ϩ release and buffering conditions would be necessary to fully test this conclusion.
The firing produced by orexin-A was slower and less variable than predicted for the depolarizing orexin current In the final series of experiments, we examined the impact of orexin and the oeAHP on the firing pattern of DR neurons. Because these experiments were conducted with the ACSF heated to 32°C, we first confirmed that orexin-A (300 nM) produced an oeAHP under these conditions. We found that, although the input resistance of DR neurons was lower (393.6 Ϯ 31.4 M⍀; n ϭ 22; normal ACSF with ionotropic receptor blockers), orexin-A still significantly increased both the amplitude (control: 7.84 Ϯ 0.58 mV; orexin: 9.17 Ϯ 0.71 mV, n ϭ 22; paired t test: t (21) ϭ 4.10, p Ͻ 0.05, paired t test) and duration (control: 0.30 Ϯ 0.03 s; orexin: 0.55 Ϯ 0.04 s, n ϭ 22; paired t test: t (21) ϭ Ϫ5.37, p Ͻ 0.05, paired t test) of the late AHP, although, not surprisingly, these changes were smaller than observed at room temperature. Twelve cells were recovered and 10 of 12 were TpH ϩ . Increasing the late AHP during the orexin-mediated depolarization might be expected to produce slower firing than the depolarization alone. Testing this prediction is complicated by the lack of blockers specific for just the oeAHP, and by the fact that orexin inhibits the A-current and produces a large increase in membrane noise, both of which could increase firing (White et al., 2000) . For the oeAHP to decrease orexin-induced firing, the orexin-mediated depolarization would have to produce interspike intervals short enough to be influenced by the oeAHP, and the oeAHP would have to play a more dominant role than A-current and membrane noise in setting the spike interval. In the first test, we injected a previously recorded noisy orexin current (virtual current) scaled to different average values and compared the resulting firing rate (without an oeAHP; Fig. 9A1 ) with the firing rate evoked by an actual orexin current (with the oe-AHP; Fig. 9A2 ) produced by application of orexin-A (300 nM). The magnitude of the actual current was estimated by the injected current necessary to return membrane potential to baseline during the peak effect of orexin-A (Fig. 9A2, arrow) . The firing rate, measured as spikes per second (sps), achieved during orexin-A application was lower than that produced by the comparable virtual current (Fig. 9A1) , and this firing rate (ϮSD) fell below the rate-current curve produced by a bracketing range of virtual currents (Fig. 9A3) . In a second test, we used a dynamic clamp to introduce a virtual orexin conductance (0.5-2 nS) to generate a noisy, depolarizing orexin current (without the oeAHP). This orexin current was comparable with that produced by 300 nM orexin in these and previous DR recordings ( Kohlmeier et al., 2008) . We compared the firing evoked by this conductance to the firing produced by subsequent application of orexin-A (300 nM). This also showed that the firing rate evoked by the actual orexin-A current (Fig. 9B2 ) was lower than that produced by the comparable virtual conductance (Fig. 9B1) , and that this firing rate fell below the firing rate-average current curve produced by a range of virtual conductances (Fig. 9B3) . These results are sum-marized in Figure 9C1 and indicate that the average steady-state firing rate expected from the virtual inward orexin currents without the oeAHP was significantly higher than the firing rate evoked by orexin-A with the oeAHP. This was true for cells tested with both current clamp (virtual: 2.8 Ϯ 0.5 sps vs actual: 1.9 Ϯ 0.3 sps; paired t test: t (4) ϭ 3.81, p Ͻ 0.05, n ϭ 5) and dynamic clamp (virtual: 1.9 Ϯ 0.5 sps vs actual: 1.2 Ϯ 0.5 sps; paired t test: t (5) ϭ 3.63, p Ͻ 0.05, n ϭ 6).
We next tested the idea that the oeAHP would promote more regular firing of DR neurons. We compared the SD of the steadystate firing rate produced by orexin-A with that produced by a corresponding virtual orexin conductance delivered by dynamic clamp. Consistent with a role for the oeAHP in promoting more regular firing, the firing rate variability produced by orexin-A was lower than that produced by dynamic clamp (Fig. 9C2 , vertical diamonds; virtual SD: 0.73 Ϯ 0.12 vs actual SD: 0.32 Ϯ 0.06, paired t test: t (5) ϭ 3.80, p Ͻ 0.05, n ϭ 6). The same decrease in variability was not observed when comparing the firing rate variability produced by orexin-A with that estimated by current clamp (virtual SD: 0.36 Ϯ 0.07 vs actual SD 0.29 Ϯ 0.06, paired t test: t (4) ϭ 1.07, p Ͼ 0.05, n ϭ 5) because the current-clamp stimulus produced significantly less firing rate variability than did the virtual conductance (unpaired t test: t (9) ϭ 2.49, p Ͻ 0.05). This lower variability possibly reflects more effective low pass filtering of the noisy current command by the membrane because there was not a corresponding fluctuation in conductance as introduced by the dynamic clamp.
Orexin-A slows steady-state firing and decreases steady-state firing fidelity To examine how orexin alters responsiveness of DR neurons to other excitatory inputs, we examined the repetitive firing evoked by suprathreshold current steps (5 s, 50 -150 pA) delivered from the same baseline membrane potential before and after orexin application. DR neurons show rapid SFA, with the initial firing rate decaying to steady-state firing in only a few interspike intervals. If the oeAHP plays an important role in regulating spiking, we would expect orexin application to increase SFA by reducing steady-state firing. Indeed, application of orexin-A (300 nM) increased SFA by increasing the interval between spikes after the first two spikes and by lowering the steady-state rate (Fig. 10A) . While orexin-A had no significant effect on the initial rate (Fig. 10B) , it significantly lowered steady-state firing for each current tested ( Fig. 10C ; repeatedmeasures ANOVA: F (1,29) ϭ 14.81, p Ͻ 0.05; post hoc tests p Ͻ 0.05; n ϭ 5). and DC (open vertical diamonds; n ϭ 6) simulated orexin currents (virtual). *p Ͻ 0.05, the ssFR firing produced by orexin-A (Actual) was significantly slower than firing produced by corresponding CC and DC virtual current. C2, Summary of firing rate variability, measured by the SD of steady-state firing rate produced by orexin-A (Actual) and by the corresponding virtual orexin conductances (Virtual). *p Ͻ 0.05, the SD produced by orexin-A was significantly lower than that produced by the corresponding DC virtual current.
Finally, we examined the effect of orexin on the fidelity with which DR neurons could fire action potentials in response to trains of brief suprathreshold current pulses. If the oeAHP plays an important role in regulating excitability dynamics, we expect that orexin would produce a decrease in firing fidelity following spiking onset and the development of the oeAHP. To test this, the pulse amplitude was adjusted to produce a spike for 100% of pulses delivered at 5 Hz (100% fidelity; Fig. 10D ), which is near the average rate during active-waking for mouse 5-HT neurons (Sakai, 2011). As predicted, after the first few spikes, orexin produced a decrease in firing fidelity (i.e., increased spike failures; repeated-measures ANOVA: F (1,49) ϭ 27.32, p Ͻ 0.05, n ϭ 5) that was evident at 5 and 10 Hz ( Fig. 10E ; post hoc tests, p Ͻ 0.05, n ϭ 5). This had the effect of compressing the steady-state inputoutput frequency relationship (Fig. 10F ) without changing the initial input-output relation of 1:1 (Fig. 10F, dotted line) .
Of these 10 neurons tested at 32°C, and 10 more tested at room temperature, which all showed a significant decrease in steady-state firing, 10 filled neurons were recovered and 8 of 10 were TpH-immunopositive.
Discussion
Here we elucidated a new action of orexin that enhanced the AHP of 5-HT DR neurons via two distinct mechanisms. We then demonstrated how this action impacts the integrative properties of these neurons.
Distinct currents underlie the oeAHP
Complete dependence of the oeAHP on Ca 2ϩ influx and elevation of [Ca 2ϩ ] i , along with a reversal potential that shifts with E K in a Nernstian manner, indicate involvement of Ca 2ϩ -activated K ϩ channels rather than the electrogenic Na ϩ /K ϩ ATPase, as found for some Ca 2ϩ -independent sAHPs (e.g., Pulver and Griffith, 2010; Gulledge et al., 2013) . Application of apamin revealed that approximately half of I oeAHP resulted from augmented I SK (tau ϳ0.5 s), whereas the remainder resulted from induction of a slow-AHP-like current (tau ϳ5.0 s).
SK augmentation depends on increased spike-evoked Ca

2؉
influx resulting from A-current inhibition and CICR SK current likely derives from SK2 and/or SK3 subunits because mRNA and protein for both localize to the DR (Stocker and Pedarzani, 2000; Sailer et al., 2004) . Because the PP2A antagonist okadaic acid did not attenuate the SK component of I oeAHP (Fig.  6A) , we examined involvement of SK-regulating Ca 2ϩ sources. Like the ␣-1 adrenoceptor enhancement of SK-AHPs in DR neurons (Pan et al., 1994) , the SK component of the oeAHP was inhibited by Ca 2ϩ -store depletion. This ␣-1 action reportedly involves IP3Rs because IP3 injection transiently (Ͻ1 min) lengthened the AHP (Freedman and Aghajanian, 1987) . This, however, did not increase the AHP amplitude, and this effect was not prolonged by inhibiting IP3 breakdown. In contrast, the orexin-mediated SK enhancement was inhibited by antagonists of RyRs, rather than IP3Rs, and it was not mimicked by IP3 uncaging, which fits with robust RyR2 and minimal IP3R expression within DR (Allen Brain Atlas; www.brain-map.org).
Because these findings suggested CICR involvement, we examined whether orexin enhanced spike-evoked Ca 2ϩ influx and found that orexin broadened both individual action potentials and CACs (Fig. 7) . Instead of directly augmenting Ca 2ϩ channel function (Kohlmeier et al., 2008) , we found that orexin inhibited a subthreshold A-current (Fig. 8) , which is likely critical because 4-AP (Fig. 7) both prolonged baseline I SK and occluded orexinmediated SK enhancement, whereas I SK produced by Ca 2ϩ uncaging pulses was not enhanced by orexin (Fig. 8) . Because Kv4.3 mRNA is differentially expressed in the DR (Serô dio et al., 1998) , it is likely that spike broadening and increased Ca 2ϩ influx result from orexin-mediated inhibition of A-current, mediated by Kv4.3 channels. This is a novel orexin action, although orexin can inhibit (Yang and Ferguson, 2003; Murai and Akaike, 2005) or increase (Belle et al., 2014) unidentified delayed-rectifier currents in some other neurons.
Strikingly, ␣-1 receptors also inhibit A-current in DR neurons (Aghajanian, 1985) . This was suggested to increase firing by shortening the interspike interval, although spike width and Ca 2ϩ influx were not examined. We confirmed that PE (3 M) also increased CACs in our slices (M.I. and C.S.L., unpublished observations), suggesting that A-current inhibition, spike broadening, and increased Ca 2ϩ influx may also contribute to ␣-1 enhancement of SK-AHPs in these neurons. Indeed, PE occluded the entire oeAHP (Fig. 1E) , suggesting that ␣-1 and OxRs share effectors or signaling components downstream of the receptors because ␣-1 actions remained intact in the absence of OxRs (Fig.  2D) . These findings fit well with the previous demonstration that orexin and ␣-1 receptor signaling converges in activating inward current in DR neurons (Brown et al., 2002) .
The apamin-insensitive component of I oeAHP differs from the classical I sAHP In contrast to SK enhancement, the apamin-insensitive component of I oeAHP decayed ϳ10 times slower (tau ϳ5 s; Fig. 4F ) and was absent before orexin application. Moreover, it was insensitive to store depletion and was not induced or occluded by blocking A-current, but it was induced by intracellular uncaging of Ca 2ϩ , indicating different Ca 2ϩ requirements. Its slow time course is reminiscent of the I sAHP (Vogalis et al., 2003) and, like the sAHP (Lee et al., 2005a) , its duration was reduced at elevated temperatures. Channels underlying the sAHP have been difficult to identify, and evidence suggests that different K ϩ channels are involved (for review, see Vogalis et al., 2003; Andrade et al., 2012) . Recently, UCL2077 was shown to block the I sAHP in hippocampal pyramidal neurons (Shah et al., 2006) and the orexininhibited I sAHP in PVT neurons (Zhang et al., 2010) . UCL2077 blocks KCNQ1/2 channels, and knock-out evidence suggests involvement of KCNQ2/3 in sAHPs of CA3 and dentate gyrus neurons (Tzingounis and Nicoll, 2008; Tzingounis et al., 2010) . Nevertheless, KCNQ antagonists are not universal blockers of classical sAHPs (Abel et al., 2004) .
Another feature of the classical I sAHP is their suppression by some neurotransmitters. Monoamines suppress it via cAMP/ PKA signaling (Madison and Nicoll, 1986; Pedarzani and Storm, 1993) , and receptors that reduce cAMP, such as adenosine A 1 and GABA B receptors, can modestly increase I sAHP in hippocampal neurons (Haas and Greene, 1984; Gerber and Gähwiler, 1994). However, unlike I sAHP in the hippocampus, forskolin did not alter the oeAHP (Fig. 5I ) . In the hippocampus, G q activation by acetylcholine and glutamate also inhibits I sAHP , and I sAHP is suppressed by orexin in PVT neurons via PKC activation (Zhang et al., 2010) . Unlike those sAHPs, PKC inhibitors did not alter I oeAHP or the ␣-1 augmentation of the SK-AHP (Pan et al., 1994) in DR neurons. Nevertheless, PDBu powerfully suppressed the entire I oeAHP , as reported for ␣-1 actions (Pan et al., 1994) . This suggests that PKC activation is not required for the oeAHP, but that global activation suppresses orexin and ␣-1-receptor signaling, perhaps via receptor internalization or desensitization (Chuang et al., 1996; Kelly et al., 2008) . Thus, while the apamin-insensitive component of I oeAHP shares features with classical sAHPs, insensitivity to forskolin, PKC inhibitors and a KCNQ blocker indicates it is novel.
Signaling cascades mediating I oeAHP
OxRs are generally thought to activate PLC via G q/11 , although their signaling is less well explored in CNS than expression systems, where OxRs couple to multiple G-proteins and second messenger systems (for review, see Kukkonen and Leonard, 2014) . Intracellular application of the PLC inhibitor U73122, but not its inactive analog U73343, completely blocked orexin-mediated inward current and the oeAHP, but not a PLC-independent 5-HT-mediated outward current (Fig. 5A-D) . This fits with expression system evidence for prominent PLC activation (Holmqvist et al., 2002) and findings from some other neurons, where PLC inhibitors attenuate orexin actions (Muroya et al., 2004; Borgland et al., 2006) . However, because neither the inward current nor I oeAHP depended on IP3 or PKC activation, noncanonical PLC signaling may be involved. While possibilities abound, one consideration is that U73122 has off-target or indirect effects that influence orexin stimulation of PLA2 (Turunen et al., 2012) and that arachidonic acid or its metabolites regulate the inward current and/or the oeAHP. Alternatively, PLC-generated DAG may be converted to the endocannabinoid 2-AG by DAGlipase, and 2-AG or its metabolites are involved. Expressed OxRs powerfully stimulate 2-AG and arachidonic acid production (Turunen et al., 2012) , and inhibition of DAG-lipase blocks OxRmediated endocannabinoid inhibition of excitatory input to DR neurons (Haj-Dahmane and Shen, 2005) . It is therefore noteworthy that both arachidonic acid and 2-AG can directly inhibit Kv4 channels (Amoró s et al., 2010) and broaden action potentials (Keros and McBain, 1997) .
Functional consequences of the oeAHP
The oeAHP enhanced SFA by reducing steady state, but not initial firing, in response to current steps (Figs. 9; 10), consistent with functions for slow, Ca 2ϩ -dependent AHPs (Faber and Sah, 2003) . Dynamic clamp studies revealed that the oeAHP decreases firing-rate variability, an effect particularly relevant in vivo, where the coefficient of variation of firing is ϳ10-fold greater (coefficient of variation 0.5-1.0; waking) (Sakai, 2011) than in our slices (coefficient of variation 0.06 -0.1). Increased SFA implies reduced excitability for tonic input, as demonstrated by late spikefailures for pulse-train inputs (5, 10 Hz; Fig. 10 D, E) and a compressed steady-state input-output relation (Fig. 10F ) . This reflects the high-pass filter function of SFA (Benda and Herz, 2003) , which favors spike encoding of rapidly varying inputs. We hypothesize that, during active waking, when orexin neuron firing is highest (Lee et al., 2005b; Mileykovskiy et al., 2005) , released orexin will both depolarize and sharpen the high-pass filter characteristics of 5-HT neurons. The oeAHP would help limit and regularize firing in response to tonic input without attenuating the spike encoding of phasic synaptic inputs related to behav-ioral events (Hajó s et al., 2007; Ranade and Mainen, 2009; Sakai, 2011; Liu et al., 2014) . This may be especially important for processing reward signals because orexin neurons increase firing during anticipation and acquisition of reward and the firing of most 5-HT DR neurons transition from a tonic increase to a burst during reward acquisition (Li et al., 2016) . Thus, orexin inputs could provide an arousal/attention signal that promotes phasic over tonic outflow from raphe neurons, which could affect the relative engagement of postsynaptic and autoreceptors by released 5-HT (Gartside et al., 2000) . Accordingly, the loss of orexin signaling in narcolepsy would be expected to impair this signal processing, potentially contributing to the expression of narcolepsy/cataplexy symptoms (Hasegawa et al., 2014) and comorbid symptoms, such as depression, anxiety, and eating disorders (Fortuyn et al., 2011) .
